BABA vs CVEO

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

CVEO exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating deteriorating financial health. While the stock has seen recent price appreciation, it is fundamentally overvalued with an extreme PEG ratio of 191.60 and a forward P/E of 58.26. Profitability remains negative with an ROE of -9.76% and a consistent track record of missing earnings estimates (0/4 beats in the last year). The current valuation is disconnected from the company's operational performance and poor deterministic health scores.